CONCLUSIONS
Benralizumab (anti-IL-5 receptor antibody) significantly reduces the size of nasal polyps, nasal blockage score, and rates of anosmia after 20 weeks therapy compared to baseline. The ratio of blood eosinophil to positive allergen skin prick tests may help predict which patients benefit the most from this biologic therapy.
Acknowledgement : We thank Jeanne Hoddinott, RN for her excellent clinical and technical assistance.